Cumberland Pharmaceuticals, Inc.
$918.2K 3,940 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Access Vascular Inc
Access Vascular Inc reported $913,965.30 across General Payments, Research, and Ownership to 47 physicians and teaching hospitals across 56 transactions.
- $914.0K Above-median payer
- All-tracks total
- 56 Below-median volume
- Transactions
- 47 Below-median reach
- Recipients
- +$6.6K
- General Payments vs PY2023
Access Vascular Inc reported $913,965.30 across all CMS Open Payments tracks (General + Research + Ownership) to 47 physicians and teaching hospitals in Program Year 2024 - ranking #643 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $26,975.18, averaging $19.4K per recipient.
How Access Vascular Inc's $914.0K all-tracks total breaks down
Access Vascular Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
15/100
Total payments
F
18/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer access-vascular-inc Access Vascular Inc
$914.0K · #643/1,925 · 0.0% industry · PY2024
- TOT $914.0K
- RANK #643
- SHARE 0.0%
- TXN 56
- RCP 47
- CAT 2
- GEN $27.0K
- ΔGEN +$6.6K
- TOP1 36.8%
- PY 2024
Volume peers
Nearest volume peer: Cumberland Pharmaceuticals, Inc. ($918.2K)
Access Vascular Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Access Vascular Inc's CMS-reported General Payments increased by $6.6K (+32.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ACCESS VASCULAR INCPY2023: ACCESS VASCULAR INCPY2024: Access Vascular Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $20,415.64
- PY2024
- $26,975.18
What the Data Shows for Access Vascular Inc
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Access Vascular Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
10 transactions worth $24.2K make "Consulting Fee" the top general-payment category in the 2-category breakdown below, 89.9% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 2 types of general payments, Access Vascular Inc's largest category was "Consulting Fee" at $24.2K - 89.9% of General Payments.
How Access Vascular Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $24.2K | 10 | 89.9% |
| Food and Beverage | $2.7K | 37 | 10.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $23,318.27 (86.4%) of $26,975.18 in this company's General Payments records across 30 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Access Vascular Inc
The five named recipients with the highest reported General Payments from this company
- 1
Michael R Jaff
$9,936.06 across 2 reported transactions
- 2
David L Longworth
$7,794.93 across 3 reported transactions
- 3
Brian T Jankowitz
$2,887.50 across 1 reported transactions
- 4
Gary M Ansel
$1,692.85 across 1 reported transactions
- 5
Michael T Mccurdy
$1,006.93 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Access Vascular Inc's spend rank (#643 of 1,925, top 33% by spend) and concentration rank (#675 of 1,838, top 37% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Medela AG : $14.7K total payments, HHI 2395
- Kyowa Kirin Co., Ltd : $41.2K total payments, HHI 2391
- Miach Orthopaedics, Inc. : $1.0M total payments, HHI 2381
- SNAP Diagnostics LLC : $515.0K total payments, HHI 2374
- DeRoyal Industries, Inc. : $17.5K total payments, HHI 2374
- AGEPHA Pharma FZ LLC : $93.7K total payments, HHI 2373
- Access Vascular Inc (this company) : $27.0K total payments, HHI 2373
- FloSpine LLC : $48.7K total payments, HHI 2372
- RedDress USA, Inc. : $184.0K total payments, HHI 2360
- Cornerstone Specialty Network LLC : $120.5K total payments, HHI 2356
- Osteoremedies, LLC : $396.8K total payments, HHI 2355
- Avertix Medical, Inc : $164.0K total payments, HHI 2352
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Access Vascular Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Access Vascular Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Access Vascular Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
ImmunoGen, Inc.
$919.6K 430 recipients
Compare payment profiles
Zealand Pharma A/S
$919.9K 108 recipients
Compare payment profiles
Aesculap, Inc.
$921.5K 705 recipients
Compare payment profiles
Spineology Inc.
$923.8K 1,284 recipients
Compare payment profiles
Olympus Corporation
$904.0K 593 recipients
Compare payment profiles
Put this to use
Access Vascular Inc ranks #643 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Access Vascular Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.